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ence measures and utility values for individual treat-
ment attributes. Differential toxicity attributes, that were
patient relevant and clinically signiﬁcant, were identiﬁed
from head-to-head trial data. Attributes identiﬁed were:
alopecia, weight loss, mucositis, diarrhoea, and febrile
neutropenia/neutropenic sepsis. Fourteen oncologists and
16 oncology nurses served as patient proxies given the
sensitive nature and ethical difﬁculties associated with the
patient population. Respondents considered an orthogo-
nally designed series of pair-wise choice scenarios repre-
senting incidence levels for individual toxicity attributes
(treatment features) with trade-offs in life-expectancy. 
A logistic regression was utilised to analyse the stated 
scenario pair preferences against the individual attribute
levels. Potential confounders were analysed. RESULTS:
Survey results indicate a strong preference for GC treat-
ment and a clear willingness-to-trade-time for tolerability
beneﬁts. Analysis of strength of preference for individual
attributes shows strong support for treatment features
that impact directly on QoL. CONCLUSIONS: UK
respondents displayed a clear preference for GC treat-
ment with superior toxicity offering a highly valued
health related QoL gain. These results provide encour-
agement for further exploration, possibly by extension to
the European setting. Discrete choice conjoint analysis is
a promising instrument in the outcomes assessment of
cancer therapies.
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OBJECTIVE: This analysis attempts to highlight the 
differences in response rates and toxicity between 
Gemcitabine combined with a platinum-based therapy
and other combinations of platinum-based chemother-
apy, in the treatment of non-small-cell lung cancer
(NSCLC). METHODS: This pooled analysis used
summary statistics from clinical trials published up to
December 2001. The analysis pooled odds ratios (OR)
and associated conﬁdence intervals (CI) using a ﬁxed-
effects model. The efﬁcacy outcomes considered are
responses (both partial and complete) and progressive
disease. Grade 3 and 4 toxicities are considered using the
WHO criteria for the following adverse events: alopecia,
nausea and vomiting, anaemia, neutropenia, thrombocy-
topenia and neuropathy. RESULTS: Patients receiving
Gemcitabine combined with a platinum therapy are more
likely to experience a response to treatment than patients
receiving other platinum based combinations. The OR for
complete and partial responses is 2.68, (CI 1.53–4.67)
and is 0.44 for progressive disease (CI 0.32–0.59). Gem-
citabine patients experienced fewer cases of alopecia 
(OR 0.15, CI 0.10–0.22) and neutropenia (OR 0.6, CI
0.47–0.77). In contrast, Gemcitabine patients experi-
enced a greater number of grade 3 or 4 anaemia (OR
1.92, CI 1.41–2.61) and thrombocytopenia (OR 6.76 CI
4.95–9.23) incidences. For neuropathy and nausea and
vomiting there was no evidence for any of the chemother-
apies having fewer patients experiencing toxicities. CON-
CLUSIONS: The implications of this analysis at the
patient level is that if response is of primary importance,
then on a purely clinical basis Gemcitabine should be the
treatment of choice. Gemzar based chemotherapy had a
higher number of responses and fewer adverse events 
for alopecia and neutropenia. To validate these results, a
meta-analysis should be conducted with stratiﬁcation for
key variables using patient level data.
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OBJECTIVES: At the Quebec Health Technology Assess-
ment Agency (AETMIS) in Canada we assessed whether
home chemotherapy for cancer was effective, safe, and
satisfactory to patients, and examined the cost, organi-
zational, and ethical implications, in order to make 
policy recommendations. METHODS: We carried out 
a systematic review of the scientiﬁc literature using 
the PubMed (MEDLINE 1980–present) and CancerLit
(1975–present) bibliographic databases. We supple-
mented this review with 16 semi-structured interviews
with service providers, including oncology nurses, physi-
cians, and home care coordinators, in 2 provinces 
with different organizational structures for cancer care
(Quebec and Ontario). RESULTS: Clinical effectiveness
of home cancer chemotherapy appears similar to that 
in non-home settings. Home treatment can be delivered
safely if patients are carefully selected and trained. Patient
eligibility criteria relate to learning capability, suitability
of the home environment, and geographic accessibility.
Improvements in patient quality of life at home have not
been well documented in the literature. Patient preference
and satisfaction with home therapy is supported,
although mostly among self-selected groups. Cost studies
show that home chemotherapy is less expensive than
inpatient treatment from a hospital perspective. When
home treatment is used as a substitute for outpatient
therapy, the result tends to be a cost shifting from hospi-
tals to home care organizations. Effects on costs to
patients/families require more study. Interviews with
service providers showed variable delivery, with greater
patient load capacity and uniformity of services where
hospital oncology departments or regionalized centres 
